Vicore Pharma is a biotech company focused on helping patients who suffer from rare diseases where there is currently no satisfactory treatment. Our focus is on the development of orphan drugs in fibrotic diseases.
Vicore Pharma has designed, synthesized and patented a unique collection of small, non-peptide molecules that stimulate the AT2 receptor within the Renin Angiotensin System (RAS). The RAS plays a critical role in maintaining blood pressure, as well as fluid and salt balance. The molecules could potentially be developed into a clinically important and commercially attractive new class of drugs.
The lead candidate drug, “Compound 21” (“C21”) was selected from a large number of patent-protected compounds. It is well-suited for both oral and intravenous administration.
Phase I studies has been performed and a Phase IIa study for the lead indication Idiopathic Pulmonary Fibrosis (IPF) is estimated to start during Q1 2018.
To prove the concept of AT2 receptor agonism as a basis to treat human diseases in areas where there are important unmet medical needs.
To prioritize the clinical development of C21 within idiopathic pulmonary fibrosis (IPF) and at the same time identify a second fibrosis indication within the orphan drug area.
To develop candidate drug molecules, based on the proven AT2 receptor agonism platform and through safety and clinical stages, into clinical drug entities for human acute and chronic use.
To enter into collaboration and licensing agreements with pharmaceutical companies to maximize development opportunities of company assets in harmony with company business objectives. In parallel, Vicore Pharma will continue to focus on academic relations to inspire further explorative research for various disease models.
Vicore Pharma AB was founded in 2000 based on explorative research at Uppsala University and Sahlgrenska Academy at Gothenburg University. In the early years Vicore Pharma was financed by venture capital companies, but in 2003 the ownership returned to the original founders. In 2007 Vita Nova Ventures acquired all shares in Vicore Pharma AB from the founders. In 2009 Mintage Scientific (now Vicore Pharma Holding) acquired all the shares in Vicore Pharma AB and 34% of the shares in I-Tech AB. Vicore Pharma Holding has completed eight share issues which together have brought in approx. 131 million SEK.
Per Jansson, D.D.S.
Per has held leading positions in the medical industry for more than twenty years. He has managed and successfully grown research-based start-up companies, both clinically and commercially.
Johanna Gräns, Ph.D
Regulatory Affairs Manager
Johanna has a Ph.D and expertise in pharmaceutical metabolism. She has extensive experience in preclinical interpretation and is responsible for producing and refining the regulatory documentation for C21.
Dan Isaksson, Ph.D
Senior R&D Chemist
Dan is an organic chemist and has been working in the biotech industry since 2009. A lot of the R&D work has been around formulation and controlled release of actives from various matrixes, as well as patenting promising new technologies.
Ulrike Muscha Steckelings M.D., Ph.D. and Professor in Pharmacology
Muscha has extensive research experience in the fields of the Renin Angiotensin System and the AT2 receptor, and has published numerous articles in peer reviewed journals. She also holds a clinical degree in dermatology. Muscha is a Professor of Integrative Pharmacology at University of Southern Denmark, Odense, in parallel with her role at Vicore Pharma.
Hans Jeppsson, Ph.D., Finance
Hans is a Finance professional with cross-disciplinary background in Finance and Medicine in both academic and industry settings. Several years of research and biologics to equity research analyst at Danske Bank and post-doc research at UC Berkeley. Hans works part-time as Assistant Professor in Finance at Gothenburg School of Economics and Law.
Kicki Johansson, Ph.D. Pharm
Head of Drug Development
Kicki has been responsible for the development of more than 40 new compounds in different disease areas within Astra Zeneca. Most recently she has had a position as Senior Project Leader/VP for the clinical development of oral anti-inflammatory projects within the Respiratory and Inflammatory Disease Division of AstraZeneca.
Marketing and Communication
Nina has more than 10 years’ experience of working with marketing and communication in the medical industry.
Anders Ljunggren, B.Pharm.
Anders has been working with cardiovascular projects in the pharmaceutical industry for over 30 years. His main interest is the Renin Angiotensin System (RAS). He has long experience from preclinical and clinical projects involving both ACE-inhibition and angiotensin receptor blockade.
Board of Directors
Leif is the owner of consulting firm Darner Asset Management AB. Prior to this, he was an Executive Director on the Board of Management at AkzoNobel, where he was responsible for Performance Coatings from 2008 and for Chemicals from 2004.
Other assignments: Board member at LKAB AB, Sweden, Flowserve Corporation, Dallas, US and I-Tech AB.
Göran Arvidson is CEO of Hansa Medical since April, 2015. Göran Arvidson has significant experience from the life science sector. He has been Executive Vice President and CFO of Swedish Orphan Biovitrum AB (publ), Co-founder of Biovitrum and has held senior positions with Procordia AB and Pharmacia AB. Göran holds B.Sc. in Business Administration from Stockholm School of Economics. Born 1960.
Other assignments: Board member in Immun System I.M.S. AB.
Kjell has extensive board experience in a large number of companies that are active across a range of industries.
Other assignments: Board member of WntResearch AB, Kjell Stenberg AB and CN Stenberg AB.
Peter Ström has an MBA from the Stockholm School of Economics. He has held senior positions at companies including KabiPharmacia UK (CEO) and IMSHealth Europe (VP).
Other assignments: Chairman of WntResearch AB. Board member of Stockholm Corporate Finance AB, Dentosystem Scandinavia AB. Deputy board member of Comtax Support Limited.
Göran has over twenty years’ experience in management positions in pharmaceutical and medical device companies, as well as from the CRO business area of clinical research. Göran has held senior leadership positions at Nobel Biocare, Boule Group and Carmel Pharma.
Other assignments: Board member of ITIN Holding AB (publ), Vicore Pharma AB, Protem Wessman AB and Protem Företagsförvaltning AB.
M.D., Ph.D. and Professor in Pharmacology
Professor Thomas Unger is the Scientific Director at CARIM (School for Cardiovascular Diseases) at Maastricht University in Germany. He is a world-renowned researcher and authority in the cardiovascular area, with more than 600 published articles. He has taken a special interest in research on the AT 2 receptor. Prof. Unger is also a valued speaker at international conferences in the cardiovascular area and holds important positions in international scientific organizations.
Ph.D. and Professor in Physiology
Professor Colin Sumners, located at the University of Florida in Gainesville, USA, has studied the Renin Angiotensin System for ~40 years. He has extensive experience with regard to angiotensin actions in neural tissues and has published extensively in this area. His current focus is on the protective AT2 receptor in the brain, as a target for stroke- and anti-hypertensive therapeutics.
MD, PhD, Associate Professor in CV Prevention
Dr Dahlöf is a previous board member of Vicore Pharma. He has practiced general internal medicine at the Sahlgrenska University Hospital for more than 35 years and is affiliated to the Sahlgrenska Academy, Gothenburg University. Dahlöf has a broad experience in cardiovascular research, pharmacology, drug development and clinical trials of all phases. He has iniated and led several larger multinational mortality and morbidity studies. In total Dahlöf have published more than 400 peer reviewed scientific articles in well renowned journals. He has taken an active scientific interest with the AT2 receptor for more than 20 years.